Adverse events reported after the use of recombinant human bone morphogenetic protein 2 - PubMed (original) (raw)
Adverse events reported after the use of recombinant human bone morphogenetic protein 2
Emily Jane Woo. J Oral Maxillofac Surg. 2012 Apr.
Abstract
Purpose: The US Food and Drug Administration has approved recombinant human bone morphogenetic protein 2 (rhBMP-2) (Infuse Bone Graft; Medtronic Sofamor Danek, Minneapolis, MN) as an alternative to autogenous bone graft for sinus augmentations and for localized alveolar ridge augmentations for defects associated with extraction sockets. The objective of this analysis was to characterize adverse events reported after the use of rhBMP-2 in oral and maxillofacial procedures.
Materials and methods: The US Food and Drug Administration's Manufacturer and User Facility Device Experience database contains reports of adverse events involving medical devices. The publicly available version of the database was searched for reports for the brand name Infuse Bone Graft. Descriptive statistics were used to summarize the procedures and adverse events.
Results: As of April 30, 2011, the Manufacturer and User Facility Device Experience database contained 83 reports of adverse events after oral and maxillofacial operations involving rhBMP-2. Of these reports, 55 (66.3%) described off-label uses, such as reconstruction of the mandible after fracture or cancer or alveolar cleft repair. The most commonly reported adverse events included local reactions, graft failure, infections, and other wound complications. Of the reports, 25 (30.1%) stated that the patient required additional surgery to address the reported adverse event.
Conclusions: Serious adverse events, some of which may require a second operation, can occur after the use of rhBMP-2 in oral and maxillofacial procedures. In this analysis graft, failure and pseudarthrosis were more commonly reported after off-label uses of rhBMP-2 than approved uses.
Published by Elsevier Inc.
Similar articles
- Adverse events after recombinant human BMP2 in nonspinal orthopaedic procedures.
Woo EJ. Woo EJ. Clin Orthop Relat Res. 2013 May;471(5):1707-11. doi: 10.1007/s11999-012-2684-x. Epub 2012 Nov 7. Clin Orthop Relat Res. 2013. PMID: 23132207 Free PMC article. - Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion.
Rodgers MA, Brown JV, Heirs MK, Higgins JP, Mannion RJ, Simmonds MC, Stewart LA. Rodgers MA, et al. BMJ. 2013 Jun 20;346:f3981. doi: 10.1136/bmj.f3981. BMJ. 2013. PMID: 23788229 Free PMC article. - Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review.
Faundez A, Tournier C, Garcia M, Aunoble S, Le Huec JC. Faundez A, et al. Int Orthop. 2016 Jun;40(6):1309-19. doi: 10.1007/s00264-016-3149-8. Epub 2016 Mar 10. Int Orthop. 2016. PMID: 26961193 Review. - A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.
Carragee EJ, Hurwitz EL, Weiner BK. Carragee EJ, et al. Spine J. 2011 Jun;11(6):471-91. doi: 10.1016/j.spinee.2011.04.023. Spine J. 2011. PMID: 21729796 Review.
Cited by
- A Pilot Study Evaluating Combinatorial and Simultaneous Delivery of Polyethylenimine-Plasmid DNA Complexes Encoding for VEGF and PDGF for Bone Regeneration in Calvarial Bone Defects.
D'Mello SR, Elangovan S, Hong L, Ross RD, Sumner DR, Salem AK. D'Mello SR, et al. Curr Pharm Biotechnol. 2015;16(7):655-60. doi: 10.2174/138920101607150427112753. Curr Pharm Biotechnol. 2015. PMID: 25934975 Free PMC article. - Mitigation of BMP-induced inflammation in craniofacial bone regeneration and improvement of bone parameters by dietary hesperidin.
Miguez PA, de Paiva Gonçalves V, Musskopf ML, Rivera-Concepcion A, McGaughey S, Yu C, Lee DJ, Tuin SA, Ali A. Miguez PA, et al. Sci Rep. 2024 Jan 31;14(1):2602. doi: 10.1038/s41598-024-52566-7. Sci Rep. 2024. PMID: 38297106 Free PMC article. - Tissue engineering strategies for alveolar cleft reconstruction: a systematic review of the literature.
Janssen NG, Weijs WL, Koole R, Rosenberg AJ, Meijer GJ. Janssen NG, et al. Clin Oral Investig. 2014 Jan;18(1):219-26. doi: 10.1007/s00784-013-0947-x. Epub 2013 Feb 22. Clin Oral Investig. 2014. PMID: 23430342 Review. - Osseointegrative effect of rhBMP-2 covalently bound on a titan-plasma-spray-surface after modification with chromosulfuric acid in a large animal bone gap-healing model with the Göttingen minipig.
Lingner M, Seidling R, Lehmann LJ, Mauermann E, Obertacke U, Schwarz MLR. Lingner M, et al. J Orthop Surg Res. 2018 Aug 30;13(1):219. doi: 10.1186/s13018-018-0915-x. J Orthop Surg Res. 2018. PMID: 30165865 Free PMC article. - Bone regeneration with recombinant human bone morphogenetic protein 2: a systematic review.
de Queiroz Fernandes J, de Lima VN, Bonardi JP, Filho OM, Queiroz SBF. de Queiroz Fernandes J, et al. J Maxillofac Oral Surg. 2018 Mar;17(1):13-18. doi: 10.1007/s12663-016-0988-1. Epub 2016 Dec 16. J Maxillofac Oral Surg. 2018. PMID: 29382988 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous